GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » ROA %

Tryptamine Therapeutics (ASX:TYP) ROA % : -71.89% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Tryptamine Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was A$-3.22 Mil. Tryptamine Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was A$4.48 Mil. Therefore, Tryptamine Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -71.89%.

The historical rank and industry rank for Tryptamine Therapeutics's ROA % or its related term are showing as below:

ASX:TYP' s ROA % Range Over the Past 10 Years
Min: -88.4   Med: -60.49   Max: -36.25
Current: -80.57

During the past 6 years, Tryptamine Therapeutics's highest ROA % was -36.25%. The lowest was -88.40%. And the median was -60.49%.

ASX:TYP's ROA % is ranked worse than
76.78% of 1503 companies
in the Biotechnology industry
Industry Median: -35.74 vs ASX:TYP: -80.57

Tryptamine Therapeutics ROA % Historical Data

The historical data trend for Tryptamine Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics ROA % Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROA %
Get a 7-Day Free Trial -36.25 -88.40 -60.49 -57.51 -73.15

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -83.93 -35.50 -85.32 -83.34 -71.89

Competitive Comparison of Tryptamine Therapeutics's ROA %

For the Biotechnology subindustry, Tryptamine Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's ROA % falls into.



Tryptamine Therapeutics ROA % Calculation

Tryptamine Therapeutics's annualized ROA % for the fiscal year that ended in Jun. 2023 is calculated as:

ROA %=Net Income (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=-7.13/( (13.614+5.881)/ 2 )
=-7.13/9.7475
=-73.15 %

Tryptamine Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-3.222/( (5.881+3.083)/ 2 )
=-3.222/4.482
=-71.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Tryptamine Therapeutics  (ASX:TYP) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-3.222/4.482
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.222 / 0)*(0 / 4.482)
=Net Margin %*Asset Turnover
=N/A %*0
=-71.89 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Tryptamine Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics Business Description

Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines